Last Updated : Nov 16, 2020 09:48 PM IST | Source: Reuters

EU strikes deal with CureVac for up to 405 million COVID vaccine doses

The deal with CureVac follows supply agreements the Commission has reached with AstraZeneca, Johnson & Johnson, Sanofi, and Pfizer for the supply of their pot.

Reuters

The European Commission will authorise a deal with German biotech firm CureVac on Tuesday to secure up to 405 million doses of its potential COVID-19 vaccine, the head of the European Commission, Ursula von der Leyen, said.

"I am happy to announce a new agreement. Tomorrow will authorise a new contract to secure another COVID-19 vaccine for Europeans," she said, adding that the contract with the German firm follows EU funding to the company to develop its vaccine.

Moderna says its vaccine is 94.5% effective in preventing COVID-19 

The Commission president also said she hoped to finalise a deal soon with Moderna for its COVID-19 vaccine.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
The deal with CureVac follows supply agreements the Commission has reached with AstraZeneca, Johnson & Johnson, Sanofi, and Pfizer for the supply of their potential vaccines.
First Published on Nov 16, 2020 09:48 pm